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Systemic overexpression of interleukin-22 induces
the negative immune-regulator SOCS3 and potently
reduces experimental arthritis in mice
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Abstract
Objective. High levels of IL-22 are present in serum and synovial fluid of patients with RA. As both pro- and anti-
inflammatory roles for IL-22 have been described in studies using animal models of RA, its exact function in arth-
ritis remains poorly defined. With this study we aimed to further unravel the mechanism by which IL-22 exerts its
effects and to decipher its therapeutic potential by overexpression of IL-22 either locally or systemically during ex-
perimental arthritis.
Methods. CIA was induced in DBA-1 mice by immunization and booster injection with type II collagen (col II).
Before arthritis onset, IL-22 was overexpressed either locally by intra-articular injection or systemically by i.v. injec-
tion using an adenoviral vector and clinical arthritis was scored for a period of 10 days. Subsequently, joints were
isolated for histological analysis of arthritis severity and mRNA and protein expression of various inflammatory
mediators was determined in the synovium, spleen and serum.
Results. Local IL-22 overexpression did not alter arthritis pathology, whereas systemic overexpression of IL-22 po-
tently reduced disease incidence, severity and pathology during CIA. Mice systemically overexpressing IL-22
showed strongly reduced serum cytokine levels of TNF-a and macrophage inflammatory protein 1a that correlated
significantly with the enhanced expression of the negative immune regulator SOCS3 in the spleen.
Conclusion. With this study, we revealed clear anti-inflammatory effects of systemic IL-22 overexpression during
CIA. Additionally, we are the first to show that the protective effect of systemic IL-22 during experimental arthritis
is likely orchestrated via upregulation of the negative regulator SOCS3.
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Introduction
RA is an autoimmune disease of unknown aetiology that is
characterized by chronic inflammation of the joints leading
to destruction of articular cartilage and bone. Although the
disease pathogenesis is much better understood, the
exact role of some mediators still needs to be further
unravelled. IL-22 was first described in mice as the IL-10-
related T cell–derived inducible factor a (IL-TIFa). This cyto-
kine is a member of the IL-10 family and shows 22% amino
acid identity with IL-10 [1, 2]. Moreover, murine IL-22
strongly resembles its human ortholog with an amino acid
similarity of 78% [3]. Major IL-22-producers are the Th17
cells, CD4þ T cells that are characterized by their produc-
tion of IL-17 [4]. Additionally, Th1 cells [5], Th22 cells [6,
7], cd T cells [8, 9], NK cells [10, 11], innate lymphoid cells
type 3 (ILC3) [10, 12], macrophages [13] and dendritic
cells [14], among others, have been shown to produce
IL-22. Target cells of IL-22 are mostly of the non-
hematopoietic lineage, like epithelial and stromal cells
[15]. Responses to IL-22 are initiated by binding of the
cytokine to its receptor complex consisting of an IL-22 re-
ceptor 1 (IL-22R1) and an IL-10 receptor 2 (IL-10R2) sub-
unit, the latter being shared with family member IL-10
[16]. While the IL-10R2 subunit is ubiquitously expressed,
expression of the IL-22R1 subunit is mainly restricted
to non-hematopoietic cells [17]. In addition to this
membrane-bound receptor complex, a soluble IL-22
binding protein (IL-22BP) has been identified. This protein
binds IL-22, thereby neutralizing the activity of this cyto-
kine [18, 19].
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Increased levels of IL-22 have been observed in the
serum of patients with RA as compared with healthy
controls [20–22] and in RA synovial fluid as compared
with that of OA patients [21]. The increased IL-22 serum
level in RA patients is correlated with multiple clinical
disease parameters, like the 28-joint DAS [22], serum
levels of RF [21, 22] and ACPA [21]. Furthermore, bone
erosions were shown to be more severe in patients
with high IL-22 serum levels [20–22]. The role of IL-22
has been studied extensively in animal models for
various auto-inflammatory diseases. In animal models
for IBD, IL-22 was shown to play a protective role.
Overexpression of IL-22 led to reduced intestinal inflam-
mation [23, 24], whereas blocking of IL-22 aggravated
the disease [25]. In contrast, neutralization of IL-22 ame-
liorated disease development in a murine psoriasis-like
skin inflammation model, while administration with re-
combinant IL-22 induced development of this inflamma-
tory skin disease [26]. In an animal model for airway
inflammation, blocking IL-22 ameliorated disease devel-
opment. Interestingly, mice also deficient for IL-17
showed exacerbated airway inflammation, suggesting
that in the absence of IL-17, IL-22 is protective in this
model [27]. Interestingly, reported data describing
the role of endogenous IL-22 in animal models for
RA showed mostly a pro-inflammatory role for IL-22
[28–32].
We aimed to decipher this pathogenic potential of IL-
22 during experimental arthritis by adenoviral overex-
pression either locally or systemically. We further aimed
to unravel the mechanism by which IL-22 exerts its
effects during CIA. While most studies focussing on IL-
22 in experimental arthritis used IL-22-targeting antibod-
ies or recombinant proteins, we were interested in using
a different approach: investigating the effect of IL-22 on
disease development and progression with increased
levels of local or systemic IL-22 in CIA by using adeno-
viral expression vectors. One of the major advantages of
adenoviral vectors is that they provide the most efficient
in vivo gene transfer, leading to high transgene expres-
sion within hours after injection compared with other
viral vector systems and target a wide variety of cell
types, both quiescent and proliferating cells [33]. Also
intravenously injected adenoviruses are easily taken up
by the spleen [34]. Based on the observation that IL-22
levels correlate with disease parameters in RA patients,
and that in animal models of arthritis IL-22 was predom-
inantly pro-inflammatory, we hypothesized that overex-
pression of IL-22 would aggravate arthritis. However,
during this study we showed that locally overexpressed
IL-22 did not alter CIA pathology, whereas systemi-
cally overexpressed IL-22 resulted in anti-inflammatory
effects on CIA that were accompanied by upregulation




Female DBA/1JRj mice and C57BL6N were purchased
from Janvier-Elevage (Le Genest Saint Isle, France).
Animals were used between 10 and 12 weeks of age un-
less otherwise specified and were housed under specific
pathogen-free conditions until transfer to individually
ventilated cage units after injection with adenoviral con-
structs. A standard diet and water were provided ad libi-
tum. All animal procedures were approved by the ethics
committee of the Radboud University, Nijmegen, The
Netherlands (permit RU-DEC 2013-014).
Induction of CIA
CIA was induced as described previously in DBA/1JRj
mice [35]. Arthritis development was macroscopically
scored three times a week using an arbitrary scoring
system of 0–2 per paw and 0–8 per mouse, according
to changes in redness and/or swelling of the paws. After
10 days the mice were anesthetized using 2–3% isoflur-
ane to collect serum before being sacrificed by cervical
dislocation.
Induction of K/BxN serum transfer-induced arthritis
(STIA)
K/BxN T cell receptor–transgenic mice on a C57BL/6
background (K/B) were a kind gift from Christophe
Benoist and Diane Mathis (Harvard Medical School,
Boston, MA, USA). By crossing K/B mice with NOD/Lt
animals, arthritic K/BxN mice were obtained in the
Nijmegen animal facility (permit RU-DEC 2011-187). A
total of 150 ml of serum derived from those mice was
injected i.p. in C57BL/6N mice on days 0 and 2. On
days 4 and 7 of the experiment, the knee joints were
isolated for histological analysis.
Induction of streptococcal cell wall arthritis (SCW)
Streptococcus pyogenes T12 organisms were cultured
overnight in Todd–Hewitt broth. Cell wall fragments
were prepared as described previously [36]. Arthritis
was subsequently induced by injecting 25mg SCW
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fragments intra-articularly (i.a.) in C57BL/6N mice, result-
ing in acute local inflammation. Mice were sacrificed on
day 7 and knee joints were isolated for histological
analysis.
Adenoviral vectors
The adenoviral expression vector for murine IL-22 (AdIL-
22) was kindly provided by J.K. Kolls (Tulane University
School of Medicine, New Orleans, LA, USA) and the
control adenoviral expression vector for luciferase
(AdLuc) was generated in-house. All viruses are replica-
tion deficient and have the transgene under control of a
CMV promoter. Twenty-one days after immunization
with CII, 1107 plaque-forming units (PFU) of adenovi-
ruses were injected i.a. into both knee joints for local
overexpression, or 3108 PFU of adenoviruses were
injected i.v. via the orbita plexus for systemic overex-
pression in immunized mice without clinical signs of
CIA. A total of 1107 PFU of adenoviruses were
injected i.a. in naı̈ve mice or 1 day prior to induction of
SCW arthritis or STIA.
Histology
Isolated joints were fixed for at least 4 days in 4% for-
maldehyde, decalcified in 5% formic acid for 7 days at
room temperature and subsequently dehydrated and
embedded in paraffin. Standard frontal sections of 7 mm
were mounted on SuperFrost slides (Menzel-Gläser,
Braunschweig, Germany). Haematoxylin and eosin (H&E)
staining and Safranin O (SO) staining were performed to
study pathologic features of the joint. The severity of
arthritis in the joints was scored on an arbitrary scale of
0–3, where 0 was no pathology and 3 was maximal
pathology, as previously described for three different
parameters [joint inflammation, proteoglycan (PG) deple-
tion from the cartilage matrix and bone erosion] [37].
Histopathological changes were scored on three semi-
serial sections of the joint, spaced 140mm apart, in a
blindfolded manner.
RNA isolation and quantitative real-time PCR
For RNA isolation of the synovial tissue, lateral and
medial pieces were punched out from synovium sur-
rounding the patella using a 3 mm biopsy punch (Stiefel,
Wachtersbach, Germany). The synovial punches were
pooled per knee joint and immediately frozen in liquid ni-
trogen. Subsequently the punches were disrupted and
homogenized using the MagNA Lyzer (Roche, Basel,
Switzerland). Total RNA was isolated using TRIzol re-
agent (Sigma-Aldrich, St. Louis, MO, USA), according to
the manufacturer’s protocol. After isolation, RNA was
treated with DNase and reverse transcribed into com-
plementary DNA (cDNA) as previously described [32].
Gene expression levels were determined by quantitative
PCR on the StepOnePlus sequence detection system
(Applied Biosystems, Foster City, CA, USA) using SYBR
Green technology (Applied Biosystems) and 2 mM pri-
mers (Biolegio, Nijmegen, The Netherlands). Specific
gene expression was normalized for expression of the
reference gene Gapdh. To allow for statistical analysis,
the DCt value of samples with mRNA levels below the
detection limit (>40 cycles) was set at 25. Primer
sequences can be found in Supplementary Table S1,
available at Rheumatology online.
Cytokine and chemokine measurements
Cytokine levels were determined using the Luminex
multi-analyte technology on the Luminex 200 (Bio-Rad,
Hercules, CA, USA) in combination with BioRad cytokine
kits 1:4 diluted in serum diluent according to the manu-
facturer’s protocol. To determine the levels of cytokines
in synovial washouts, patellae with surrounding soft tis-
sue consisting of the tendon and synovium were dis-
sected in a standardized manner. Patellae were cultured
in RPMI 1640 medium containing 0.1% BSA (200ml/
patella) for 1 h at room temperature. Thereafter, super-
natant was harvested and centrifuged for 5 min at
1000 g. Cytokine levels were determined using the
Luminex multi-analyte technology in 50ml of synovial
washout medium.
Statistical analysis
To determine the level of statistical significance between
means of experimental groups, the t test or a one- or
two-way analysis of variance (ANOVA) was used unless
stated otherwise. This depended on the number of ex-
perimental groups and normality testing using GraphPad
Prism version 5.03 (GraphPad Software, San Diego, CA,
USA). P-values <0.05 were considered significant.
Results
Local IL-22 overexpression did not alter CIA joint
pathology
After demonstrating that intra-articular injection of AdIL-
22 resulted in overexpression of IL-22 in a naı̈ve joint
(Supplementary Fig. S1A, available at Rheumatology on-
line), we overexpressed IL-22 locally during CIA. IL-22
levels were not monitored over time, but interestingly
we could still detect elevated levels of IL-22 in the
serum of mice 10 days after i.a. injection with AdIL-22
(Supplementary Fig. S1B, available at Rheumatology on-
line). Local IL-22 overexpression during CIA did not af-
fect synovial mRNA expression or protein serum levels
of various pro- and anti-inflammatory markers, at least
not detectable 10 days after virus injection (data not
shown, performed by Roeleveld et al.). Macroscopic
scoring showed that arthritis incidence was not affected
by local IL-22 overexpression (Fig. 1A). When analysing
the arthritis severity in the mice that did develop arth-
ritis, the total arthritis score of the four paws was only
significantly increased by IL-22 overexpression at day
28 of CIA (Fig. 1B). No difference in arthritis severity
was observed when only scoring the front legs (Fig. 1C).
Interestingly, when only the hind paws, of which the
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ipsilateral knee joints both received the virus injections,
were included in the analysis, overexpression of IL-22
slightly increased the severity of clinical arthritis at days
28 and 31, indicating a local pro-inflammatory role for
IL-22 (Fig. 1D).
By subsequent histological analysis, we aimed to un-
ravel the effect of local IL-22 overexpression on arthritis
severity in more detail. In naı̈ve mice, IL-22 overexpres-
sion induced short-term upregulation of IL-6,
Keratinocyte Chemoattractant (KC), S100A9 and recep-
tor activator of nuclear factor jB ligand (RANKL)
(Supplementary Fig. S2A, available at Rheumatology on-
line), although this was not sufficient to induce joint
pathology (Supplementary Fig. S2B and C, available at
Rheumatology online). Based on this pro-inflammatory
response and the macroscopic scores of CIA at the
time of sacrifice (day 31), we expected local IL-22 over-
expression to aggravate synovial inflammation and joint
destruction. However, as demonstrated in Fig. 2A and
B, arthritis pathology at day 31 of CIA showed no differ-
ences between AdIL-22- and AdLuc-injected knee joints
on various histological parameters (Fig. 2A and B).
Additionally, no effects of IL-22 overexpression were
found in the ipsilateral ankles (Supplementary Fig. S3,
available at Rheumatology online). To exclude that the
severity of the CIA model overruled the pro-
inflammatory effects of IL-22 overexpression, we also
applied local AdIL-22 during the immune complex–de-
pendent K/BxN serum transfer–induced arthritis and the
toll-like receptor 2–driven SCW arthritis. However, local
IL-22 overexpression did not affect joint pathology in
these arthritis models either (Supplementary Figs S4 and
S5, available at Rheumatology online).
Systemic IL-22 overexpression potently reduced
arthritis pathology
In addition to the effect of local IL-22 overexpression
during experimental arthritis, we investigated the poten-
tial of IL-22 to enhance CIA by systemic administration
of AdIL-22. Our group previously used a similar ap-
proach to demonstrate the pro-inflammatory and de-
structive effects of IL-17 [38]. Surprisingly, development
of CIA was delayed in mice injected with AdIL-22 and
FIG. 1 Local IL-22 overexpression enhances arthritis severity in the ipsilateral paws
Macroscopically scored (A; N¼ 17 mice) CIA incidence and (B) severity of the four paws or separate for (C) front and
(D) hind legs. AdLuc, n¼14 mice/group; AdIL-22, n¼13 mice/group. *P< 0.05, repeated measures ANOVA. Values
are mean (S.E.M.).
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arthritis incidence at the end of the study was clearly
reduced compared with the AdLuc-injected mice (CIA
incidence of 83% in AdLuc vs 50% in AdIL-22; Fig. 3A).
When studying arthritis severity, strikingly and signifi-
cantly reduced macroscopic scores were detected in
mice receiving systemic AdIL-22 as compared with the
AdLuc-injected control group (Fig. 3B). In line with
macroscopic inflammation, histological analysis showed
significantly reduced cellular influx into the ankle joints
of mice injected with AdIL-22 (Fig. 3C and D).
Additionally, cartilage PG depletion from these ankles
was dramatically reduced (Fig. 3C and D) and small but
significant protective effects on bone erosion were
observed (Fig. 3C). Only the mice that developed arth-
ritis were used in the analysis.
Systemic IL-22 overexpression reduces expression
of various inflammatory mediators
To investigate whether the anti-inflammatory effect of IL-
22 overexpression during CIA was accompanied by
reduced serum cytokine levels, a multi-analyte Luminex
analysis was performed. Highly elevated levels of IL-22
were detected 10 days after systemic IL-22 overexpres-
sion in CIA mice (Fig. 4), up to 200 times higher than
after local overexpression of IL-22 (Supplementary Fig.
S1B, available at Rheumatology online). Whereas serum
levels of the pro-inflammatory mediators IL-1b, IL-17,
GM-CSF and monocyte chemoattractant protein-1 were
unaltered in AdIL-22-injected mice (data not shown),
serum levels of IFN-c, TNF-a, macrophage inflammatory
protein 1a (MIP-1a) and IL-10 were significantly reduced
in these mice (Fig. 4). We performed quantitative PCR
to further investigate whether the IL-22-mediated down-
regulation of serum cytokines is reflecting reduced
synovial activation or the targeting of splenocytes, syno-
vium and spleen. Despite the strong protective effects
on macroscopic and histological scores, no significant
effects on synovial (knee joint) mRNA expression of
IFN-c, TNF-a, MIP-1a and IL-10 were observed by sys-
temic IL-22 (Supplementary Fig. S6A, available at
Rheumatology online). Only in the spleen was gene ex-
pression of IFN-c, but not of the other inflammatory
mediators, significantly reduced in AdIL-22-injected
mice (Supplementary Fig. S6B, available at
Rheumatology online). To exclude that the overexpres-
sion of IL-22 had an autocrine effect on IL-22 signalling,
we also performed gene expression analysis of IL-22
signalling molecules. However, no differences were
observed in the expression of the genes encoding for
IL-22R, IL-10Rb and IL-22BP between the control mice
and the mice overexpressing IL-22 either locally or sys-
temically (Supplementary Fig. S7ABC, available at
Rheumatology online).
To determine the B cell response in CIA mice, we per-
formed ELISA for anti-col II responses in serum of our
arthritic mice. We did not observe differences in IgG1
levels between the experimental groups (Supplementary
Fig. S8A, available at Rheumatology online), but the
serum levels of IgG2a, which is known to be pathogenic
in CIA [39], was significantly reduced in AdIL-22 system-
ically injected mice (Supplementary Fig. S8B, available
at Rheumatology online), indicating less active B cells in
CIA during IL-22 overexpression.
Systemic overexpression of IL-22 induces splenic
SOCS3 mRNA expression
To explain the anti-inflammatory effect of systemic IL-22
overexpression, we studied the effect of AdIL-22 on the
expression of the anti-inflammatory protein SOCS, an
important negative regulator of the immune system [40].
Interestingly, a strong and significant upregulation of
SOCS3 was detected in the spleen, but not synovium,
FIG. 2 Local IL-22 overexpression does not enhance synovial inflammation and joint pathology during CIA
Mice were sacrificed 10 days after virus injection (day 31 of CIA) and the knee joints were subsequently isolated for
histological analysis of cartilage PG depletion (SO stain, original magnification 100), inflammation and bone erosion
(both H&E stain, original magnification 50) (A, B; AdLuc, n¼ 16 joints/group; AdIL-22, n¼12 joints/group). Values
are mean (S.E.M.).
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of mice after systemic overexpression of IL-22 during
CIA, whereas SOCS1 levels were not significantly
affected (Fig. 5A and B).
Interestingly, a significant negative correlation be-
tween splenic SOCS3 mRNA expression and serum
levels of TNF-a (Fig. 6A) and MIP-1a (Fig. 6B) was
detected, suggesting that the observed reduction in
serum cytokine levels is mediated in a SOCS3-
dependent manner. No significant correlation was
observed for IFN-c (Fig. 6C) and IL-10 (Fig. 6D).
Discussion
Despite the numerous animal studies performed to de-
lineate the dual role of IL-22 in the development and
progression of experimental arthritis, no consensus on
this subject has been reached. While most studies
focussing on IL-22 in experimental arthritis used IL-22-
targeting antibodies or recombinant proteins, we were
interested in using a different approach: investigating
the effect of IL-22 in CIA by using adenoviral expression
vectors. One of the major advantages of adenoviral vec-
tors is that they provide the most efficient in vivo gene
transfer, leading to high transgene expression within
hours after injection, and target a wide variety of cell
types, both quiescent and proliferating cells [33].
Adenoviral vectors are the most commonly used in clin-
ical trials worldwide and account for >20% of all gene
therapy trials [41]. Intravenously injected adenoviruses
are easily taken up by the spleen and show gene ex-
pression by antigen-presenting cells [34], whereas intra-
articularly injected adenoviruses target mostly the fibro-
blasts in the synovial lining layer [42]. In our studies we
showed that local IL-22 overexpression during CIA did
not alter joint pathology, whereas systemic overexpres-
sion of IL-22 dramatically reduced the development of
FIG. 3 Systemic IL-22 overexpression during CIA reduces arthritis incidence and pathology
Mice were injected intravenously with AdIL-22 or AdLuc virus after receiving i.p. col II booster at day 21.
Macroscopically scored arthritis (A) incidence and (B) severity of the four paws (n¼12 mice/group). Ten days after
virus injection, ankle joints were isolated for histological analysis of cartilage PG depletion (SO stain, original magnifi-
cation 100), inflammation and bone erosion (both H&E stain, original magnification 50) (C, D; n¼ 24 joints/group).
*P<0.05, **P<0.01, ***P< 0.001 by (B) repeated measures ANOVA or (C) Mann–Whitney U test. Values are mean
(S.E.M.).
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arthritis, which was accompanied by upregulation of
SOCS3.
Unexpectedly, local adenoviral IL-22 overexpression
did not induce joint pathology in naı̈ve mice, nor did it
aggravate the severity of innate immune-driven arthritis
in mice with K/BxN serum transfer– or SCW-induced
arthritis. Although it caused a rapid upregulation of pro-
inflammatory cytokines and pro-destructive mediators,
we also observed that this upregulation was already
greatly diminished after 24 h, while the expression of IL-
22 peaked at this time point. This discrepancy suggests
that the early pro-inflammatory effects of IL-22 may be
subsequently inhibited by negative feedback mecha-
nisms, probably lasting too short to induce or aggravate
joint pathology.
Various publications describe a predominantly pro-
inflammatory phenotype for IL-22 during adaptive
immune-driven experimental arthritis. Blocking IL-22
suppressed arthritis in arthritic IL-1Ra/ mice [32].
Additionally, another study showed reduced severity of
CIA in IL-22/ mice on a C57BL/6 background.
However, no effects of IL-22 deficiency on disease inci-
dence were detected [30]. Another study showed a pro-
tective role for endogenous IL-22 before the onset and a
pathogenic role after the onset of CIA in DBA1- or IFN-
c-deficient mice, and the pathogenic effect of IL-22 was
suggested to be dependent on suppression of IFN-c
responses [43].
Based on these studies on downregulating IL-22 sig-
nalling, we expected that a systemic overexpression of
IL-22 would cause an aggravation of CIA development.
However, a highly significant reduction in CIA incidence
and severity was observed in our study. This protective
effect of IL-22 overexpression during CIA was confirmed
by an independent observation in a similar study design
(personal communication, F. Apparailly, INSERM U844,
France). The reduced CIA pathology observed during
systemic IL-22 overexpression was accompanied by
suppressed B cell responses as demonstrated by lower
IgG2a serum levels.
Intriguingly, the therapeutic effect of systemic IL-22
overexpression and lack of effects upon local injection
were similar to those previously reported by our group
on adenoviral overexpression of SOCS3 [44]. SOCS3
negatively regulates various cytokine signalling pathways
[40]. Whereas local SOCS3 overexpression during CIA
did not protect from arthritis development, systemic
FIG. 4 Serum protein levels of IL-22, IFN-c, TNF-a, MIP-
1a and IL-10
Mice were injected intravenously with AdIL-22 or AdLuc
virus after receiving col II booster at day 21. Mice were
sacrificed 10 days after virus injection and serum was
collected to determine protein levels using Luminex
(n¼12 mice/group; t test). *P< 0.05, **P<0.01,
***P< 0.001.Values are mean (S.E.M.).
FIG. 5 Splenic SOCS3 mRNA expression increased after systemic IL-22 overexpression
Mice with CIA were sacrificed 10 days after AdIL-22 or AdLuc virus injection (day 31 of CIA). Subsequently, (A) splenic
tissue and (B) synovium punches were isolated and relative mRNA expression of SOCS genes was determined using
quantitative PCR. N¼ 4–6 mice/group. **P< 0.01; unpaired t test. Values are mean (S.E.M.).
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SOCS3 overexpression resulted in the generation of tol-
erogenic antigen-presenting cells, impairing antigen-
specific T cell activation and thereby suppressing arth-
ritis [44]. Explaining the protective effects of IL-22
through SOCS3 induction could make sense, as IL-22
mainly signals through STAT3 [45], which may in turn
lead to the activation of a negative feedback mechanism
via SOCS3 [46]. The fact that IL-22 has been shown to
induce SOCS3 expression in lung epithelial [46] and liver
cells [47] leads to the hypothesis that a similar mechan-
ism may apply during CIA. Indeed, a significant increase
in SOCS3 mRNA expression was detected in spleno-
cytes, but not synoviocytes, from AdIL-22-injected mice.
In line with the increased SOCS3 levels, we observed
a significant reduction in IFN-c, TNF-a, MIP-1a and
IL-10 serum levels in mice upon systemic IL-22 over-
expression during CIA. This typical cytokine profile
suggests that the anti-inflammatory effect of IL-22
mainly affects cytokine production by monocytes/
macrophages, although IL-22R is mainly expressed by
non-hematopoietic cells, suggesting an indirect effect of
IL-22 on these cytokines [17]. The increased SOCS3
expression in splenocytes negatively correlated with the
reduced serum levels of TNF-a and MIP-1a, suggesting
that the observed anti-inflammatory effect of systemic
IL-22 overexpression is mediated via a SOCS3-
dependent pathway. In synovial tissue, local IL-22 did
not induce a detectable upregulation of SOCS3 expres-
sion. Probably only high doses of IL-22 induce SOCS3.
Local IL-22 levels were approximately 6-fold lower than
systemic levels at day 10 after intra-articular or systemic
overexpression. Another explanation could be the route
of administration and the target cells reached, as only
intravenously injected AdIL-22 resulted in arthritis pro-
tection and increased SOCS3 expression in the spleen,
suggesting that this is a systemic process.
Even though our IL-22-induced SOCS3 concept
explains our current data and probably more studies
using overexpression of IL-22, it cannot fully account for
historic data on the dual role of IL-22. The IL-22-
induced responses appear to depend on whether the
cytokine is endogenously expressed or exogenously
administered: whereas endogenous IL-22 plays a pro-
inflammatory role in arthritis, exogenous (high) levels of
IL-22 have been demonstrated to be anti-inflammatory
in experimental arthritis models. Additionally, it seems
that the location of recombinant protein/viral vector in-
jection is important for the outcome of the intervention.
In general, studies blocking endogenous IL-22 using
systemically applied neutralizing antibodies or geneti-
cally modified mice show reduced development of
experimental arthritis [28–32, 48], indicating a pro-
FIG. 6 Splenic SOCS3 expression negatively correlates with serum levels of TNF-a and MIP-1a
Relative splenic SOCS3 mRNA expression (2DCt100) was plotted against serum levels of (A) TNF-a, (B) MIP-1a,
(C) IFN-c and (D) IL-10. N¼ 12 mice. Pearson r correlation.
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inflammatory role for endogenous IL-22. Accordingly,
and in line with macroscopic scores of the current
study, locally injected recombinant IL-22 before arthritis
onset (slightly) exaggerated disease severity [29, 31]. In
line with our study, systemic injection of high levels of
recombinant IL-22 reduced the development of arthritis
[49]. Finally, the inflammatory context seems to affect
the magnitude of the IL-22 effects on experimental arth-
ritis: neutralization of the cytokine before arthritis onset
potently reduces disease severity, whereas these effects
have been described as absent when neutralizing IL-22
during later stages of arthritis development [48].
To date, both pro- and anti-inflammatory roles have
been described for IL-22, making it a debatable target in
the treatment of RA. However, as only high, non-
physiological concentrations of exogenous IL-22 were
demonstrated to be anti-inflammatory, and IL-22 was
shown to drive the local arthritis process using blocking
and knockout studies, therapeutic targeting of endogen-
ous IL-22 is expected to be beneficial without risk of ad-
verse inflammatory responses, contributing to reduced
pathology and symptoms in the treatment of RA. With
these studies we revealed a subtle pro-inflammatory ef-
fect of IL-22 after local overexpression. More important-
ly, a clear anti-inflammatory effect of systemic IL-22
overexpression during CIA was described that was
associated with increased gene regulation of SOCS3.
With these studies identifying SOCS3 induction by IL-
22, we have contributed to understanding the dual role
of IL-22 in arthritis.
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